Get the Stockscreener App
0.9102
1.21%
0.0109
Cytosorbents Corp stock is traded at $0.9102, with a volume of 147.71K.
It is up +1.21% in the last 24 hours and down -12.48% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.8993
Open:
$0.9062
24h Volume:
147.71K
Relative Volume:
1.28
Market Cap:
$51.95M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-1.517
EPS:
-0.6
Net Cash Flow:
$-19.17M
1W Performance:
-0.62%
1M Performance:
-12.48%
6M Performance:
+1.13%
1Y Performance:
-26.00%
1-Day Range:
$0.9062
$0.9501
1-Week Range:
$0.89
$0.97
52-Week Range:
$0.70
$2.15
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.9102 | 51.95M | 33.79M | -18.67M | -19.17M | -0.60 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
CytoSorbents to Present at Piper Sandler's 36th Annual Healthcare Conference | CTSO Stock News - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
Granahan Investment Management Reduces Stake in CytoSorbents Cor - GuruFocus.com
FY2024 EPS Estimates for Cytosorbents Decreased by Analyst - Defense World
FY2024 EPS Estimate for Cytosorbents Decreased by Analyst - MarketBeat
Cytosorbents Corporation (NASDAQ:CTSO) Q3 2024 Earnings Call Transcript - Insider Monkey
CytoSorbents And Converge Biotech Announce Strategic - GlobeNewswire
CytoSorbents Expands Into India Through Strategic Converge Biotech Partnership | CTSO Stock News - StockTitan
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - MarketBeat
CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Improved ... - Yahoo Finance
Cytosorbents Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CytoSorbents Corporation’s Q3 2024 Financial Highlights - TipRanks
CytoSorbents: Q3 Earnings Snapshot - CT Insider
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results - StockTitan
CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ah - GuruFocus.com
CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ahead of Earnings - Yahoo Finance
CytoSorbents (STU:HQE1) 3-Year EPS without NRI Growth Rate : -38.10% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 3-Year EBITDA Growth Rate : -37.70% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 3-Year FCF Growth Rate : -39.10% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 5-Day RSI : 14.64 (As of Nov. 05, 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) Operating Income : €-23.16 Mil (TTM As of Jun. 2024) - GuruFocus.com
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification - StockTitan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Cytosorbents (CTSO) to Release Earnings on Thursday - MarketBeat
Cytosorbents (NASDAQ:CTSO) and Caliber Imaging & Diagnostics (OTCMKTS:LCDX) Critical Comparison - Defense World
Analyst Scoreboard: 5 Ratings For CytoSorbents - Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts - Benzinga
FDA begins review of CytoSorbents' bleeding reduction device - Investing.com
FDA begins review of CytoSorbents' bleeding reduction device By Investing.com - Investing.com UK
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review - StockTitan
CytoSorbents (STU:HQE1) Forward Dividend Yield % : 0.00% (As of Nov. 05, 2024) - GuruFocus.com
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - MarketBeat
Cytosorbents Co. (NASDAQ:CTSO) Short Interest Down 5.7% in September - MarketBeat
CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
CytoSorbents maintains Buy rating from B.Riley with no change in target price - Investing.com
Cytosorbents announces $20 million "at the market" equity offering - Investing.com
Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits - Quantisnow
DrugSorb-ATR seeks FDA priority review for surgery bleeding - Investing.com
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update - The Manila Times
Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 81% loss from investing in the stock three years ago - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):